We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




PSA Can Help Identify Cancer Following Surgery for Benign Prostatic Hyperplasia

By LabMedica International staff writers
Posted on 09 Jul 2009
Men undergoing surgical interventions for benign prostatic hyperplasia (BPH) are still at risk for subsequent development of prostate cancer due to residual tissue, claims a new study. More...


Researchers at Northwestern University (Chicago, IL, USA) conducted a retrospective review of 525 patients who had undergone one of three procedures for BPH: transurethral resection of the prostate (TURP; 343 patients), holmium laser resection of the prostate (HoLRP; 54 patients), or open prostatectomy (OP; 68 patients), between 1992 and 2007. The prostate-specific antigen (PSA) and PSA velocity values were collected at regular intervals both pre- and postoperatively for all patients, since the researchers hypothesized that the PSA level might be influenced by the efficacies of different BPH procedures. Only patients with histologic BPH and those with incidental prostate cancer who underwent a watchful waiting strategy were included.

The researchers found that the average preoperative PSA values were significantly different between the TURP, HoLRP, and OP groups. Only one patient had incidental prostate cancer in the HoLRP group. No differences were present between the preoperative PSA values for patients with histologic BPH and those with incidental prostate cancer undergoing a watchful waiting strategy. However, the postoperative PSA values were increased in the patients with prostate cancer; similarly, patients with incidental prostate cancer had a significantly elevated postoperative mean PSA velocity compared with patients without prostate cancer. The researchers therefore concluded that postoperative PSA and PSA velocity measurements could be used to distinguish patients with prostate cancer from those with histologic BPH only. The study was published ahead of print on May 8, 2009, in the online edition of Urology.

Prostatic adenoma inevitably remains after BPH surgery, and studies have determined that the level of PSA decreases by approximately 0.1-0.3 ng/ml for every gram of prostate tissue removed. Therefore, PSA levels should indicate residual hyperplastic tissue, as well as resulting cancer risk.

Related Links:

Northwestern University



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.